Opko Health Inc (OPK) Stock Price, Quote & News

Company Profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 305 575 4100

Website: www.opko.com

Address:

4400 Biscayne Boulevard, Miami, United States

crett Jun. 4 at 9:54 PM

$OPK .

0 · Reply

tymtested Jun. 4 at 9:48 PM

$OPK Open season for DIP BUYING!!

0 · Reply

Gasbagger Jun. 4 at 9:03 PM

$OPK It’s funny how the Longs are still trying to manipulate the market by trading a few shares, aftermarket , to higher the price.

0 · Reply

crett Jun. 4 at 5:55 PM

$OPK Im in.

0 · Reply

Gasbagger Jun. 4 at 5:07 PM

$OPK has never followed the Nasdaq . Fact...Frost has turned Opko into a very bad investment because he operates it like his own personal piggy bank.

0 · Reply

Gasbagger Jun. 4 at 12:07 PM

$OPK bills=clown

0 · Reply

tymtested Jun. 4 at 1:00 AM

$OPK statistical probability indicates opko rally could go on 40+ weeks because the base formed across multi year. GO OPKO!

0 · Reply

tymtested Jun. 4 at 12:45 AM

$OPK the only sellers are penny flippers while the stock is headed up. Otherwise, supply of selling is exhausted and more big buyers are accumulating, more aggressively than the sellers.

0 · Reply

tymtested Jun. 3 at 9:51 PM

$OPK new room to run! Bolinger band raised and the resistance raised. GO OPKO!

0 · Reply

tymtested Jun. 3 at 6:19 PM

$OPK get ready for another leg up!! starting to break through resistance!! BIG BUYERS have stepped into the ring!!

0 · Reply

OPKO Health Transcript: Jefferies Global Healthcare Conference 2026

May 15, 2026, 8:00 AM EDT - 20 days ago

OPKO Health Proxy statement: Proxy filing

May 12, 2026, 8:00 AM EDT - 23 days ago

OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

May 8, 2026, 7:00 AM EDT - 27 days ago

OPKO Health Slides: Corporate presentation

Apr 30, 2026, 8:30 AM EDT - 5 weeks ago

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

OPKO Health Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

OPKO Health Proxy statement: Proxy filing

2026-04-29T12:37:59.000Z - 5 weeks ago

Opko Health downgraded to Market Perform from Outperform at Barrington

Apr 28, 2026, 4:30 PM EDT - 5 weeks ago

OPKO Health Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 5 weeks ago

OPKO Health Earnings release: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 5 weeks ago

OPKO Health Quarterly report: Q1 2026

Apr 28, 2026, 4:05 PM EDT - 5 weeks ago

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

Apr 21, 2026, 4:05 PM EDT - 6 weeks ago

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

2026-03-02T14:20:11.000Z - 3 months ago

Opko Health price target lowered to $1.50 from $2.25 at Barrington

Feb 27, 2026, 8:00 AM EST - 3 months ago

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

Feb 26, 2026, 4:30 PM EST - 3 months ago

OPKO Health Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

OPKO Health Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

OPKO Health Earnings release: Q4 2025

Feb 26, 2026, 4:05 PM EST - 3 months ago

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

Feb 12, 2026, 8:00 AM EST - 4 months ago

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

2026-02-04T13:16:35.000Z - 4 months ago

Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet

ENTX

Feb 4, 2026, 8:00 AM EST - 4 months ago

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

Jan 14, 2026, 4:30 PM EST - 5 months ago

OPKO Health Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:11 PM EST - 5 months ago

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 6 months ago

OPKO Health Slides: Corporate presentation

2025-11-20T09:50:09.000Z - 7 months ago

Opko Health initiated with a Neutral at JPMorgan

Nov 19, 2025, 4:05 PM EST - 7 months ago

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

2025-10-30T20:10:16.000Z - 7 months ago

Opko Health downgraded to Hold from Buy at Jefferies

2025-10-29T20:36:22.000Z - 7 months ago

Opko Health reports Q3 EPS 3c, consensus (5c)

Oct 29, 2025, 4:30 PM EDT - 7 months ago

OPKO Health Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

OPKO Health Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

OPKO Health Earnings release: Q3 2025

Oct 29, 2025, 4:05 PM EDT - 7 months ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

2025-10-29T12:10:25.000Z - 7 months ago

Opko Health’s ModeX enters license, collab agreement with Regeneron

REGN

2025-10-28T12:21:29.000Z - 7 months ago

Opko Health’s ModeX Therapeutics begins trial of MDX2004

Oct 22, 2025, 4:05 PM EDT - 8 months ago

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

2025-09-22T12:00:42.000Z - 9 months ago

Opko Health management to meet with Barrington

Sep 15, 2025, 8:30 AM EDT - 9 months ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Jul 31, 2025, 4:30 PM EDT - 11 months ago

OPKO Health Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 11 months ago

OPKO Health Quarterly report: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 11 months ago

OPKO Health Earnings release: Q2 2025

Jul 31, 2025, 4:05 PM EDT - 11 months ago

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

Jun 30, 2025, 8:01 AM EDT - 1 year ago

NextPlat Issues Interim CEO Update Shareholder Letter

NXPL

Jun 25, 2025, 11:00 AM EDT - 1 year ago

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

2025-06-25T12:10:46.000Z - 1 year ago

Entera Bio, Opko Health announce new in vivo data for OPK-88006

ENTX

2025-06-25T12:10:37.000Z - 1 year ago

Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025

ENTX

2025-06-09T12:21:02.000Z - 1 year ago

Opko Health’s ModeX forms Scientific Advisory Board

Jun 4, 2025, 11:05 AM EDT - 1 year ago

OPKO Health Transcript: Jefferies Global Healthcare Conference 2025

May 20, 2025, 9:00 AM EDT - 1 year ago

OPKO Health Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

OPKO Health to Participate in Two Upcoming Investor Conferences

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Quarterly report: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings release: Q1 2025

2025-04-25T09:15:19.000Z - 1 year ago

Opko Health initiated with a Neutral at JPMorgan

2025-04-04T12:10:48.000Z - 1 year ago

Opko Health board authorizes $100M increase to existing share repurchase program

Apr 4, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

2025-03-25T18:57:10.000Z - 1 year ago

Opko Health management to meet with Piper Sandler

2025-03-17T21:50:06.000Z - 1 year ago

Opko Health CEO buys $348K in common stock

Mar 17, 2025, 8:57 AM EDT - 1 year ago

OPKO and Entera partner to develop obesity pill

Mar 14, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings release: Q4 2024

Feb 27, 2025, 4:10 PM EST - 1 year ago

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

Jan 15, 2025, 6:00 PM EST - 1 year ago

OPKO Health Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

OPKO Health Slides: FY 2025

Jan 9, 2025, 11:45 AM EST - 1 year ago

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 1:30 PM EST - 1 year ago

OPKO Health Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 18, 2024, 8:00 AM EST - 1 year ago

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

NXPL

Nov 14, 2024, 6:00 AM EST - 1 year ago

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

BABA NXPL

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings release: Q3 2024

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Oct 7, 2024, 8:00 AM EDT - 1 year ago

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

NXPL

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Aug 30, 2024, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing

Aug 7, 2024, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

OPKO Health Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

OPKO Health Earnings release: Q2 2024

Aug 7, 2024, 4:06 PM EDT - 1 year ago

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

Jul 17, 2024, 4:14 PM EDT - 2 years ago

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

Jun 6, 2024, 10:30 AM EDT - 2 years ago

OPKO Health Transcript: Jefferies 2024 Global Healthcare Conference

May 31, 2024, 10:48 AM EDT - 2 years ago

OPKO Health to Participate in the Jefferies Global Healthcare Conference

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings Call Transcript: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Quarterly report: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings release: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

May 3, 2024, 8:00 AM EDT - 2 years ago

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Mar 5, 2024, 8:52 AM EST - 2 years ago

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Feb 29, 2024, 7:00 AM EST - 2 years ago

OPKO Health Proxy statement: Proxy Filing

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Annual report: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings release: Q4 2023

Feb 27, 2024, 4:05 PM EST - 2 years ago

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Feb 22, 2024, 4:05 PM EST - 2 years ago

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

Feb 16, 2024, 7:00 AM EST - 2 years ago

OPKO Health Proxy statement: Proxy Filing

Jan 10, 2024, 6:45 PM EST - 2 years ago

OPKO Health Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 4:05 PM EST - 2 years ago

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

Jan 4, 2024, 11:31 PM EST - 2 years ago

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Jan 3, 2024, 5:05 PM EST - 2 years ago

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Nov 28, 2023, 7:00 AM EST - 2 years ago

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Nov 7, 2023, 6:45 AM EST - 2 years ago

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

SOPH

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Quarterly report: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Earnings release: Q3 2023

Nov 6, 2023, 4:05 PM EST - 2 years ago

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 2, 2023, 10:00 AM EDT - 2 years ago

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Oct 31, 2023, 8:00 AM EDT - 2 years ago

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 25, 2023, 4:25 PM EDT - 2 years ago

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

Sep 28, 2023, 4:08 PM EDT - 2 years ago

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Aug 3, 2023, 4:30 PM EDT - 3 years ago

OPKO Health Earnings Call Transcript: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

OPKO Health Quarterly report: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

OPKO Health Earnings release: Q2 2023

Jul 25, 2023, 4:05 PM EDT - 3 years ago

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

Jun 28, 2023, 6:45 AM EDT - 3 years ago

FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

PFE

crett Jun. 4 at 9:54 PM

$OPK .

0 · Reply

tymtested Jun. 4 at 9:48 PM

$OPK Open season for DIP BUYING!!

0 · Reply

Gasbagger Jun. 4 at 9:03 PM

$OPK It’s funny how the Longs are still trying to manipulate the market by trading a few shares, aftermarket , to higher the price.

0 · Reply

crett Jun. 4 at 5:55 PM

$OPK Im in.

0 · Reply

Gasbagger Jun. 4 at 5:07 PM

$OPK has never followed the Nasdaq . Fact...Frost has turned Opko into a very bad investment because he operates it like his own personal piggy bank.

0 · Reply

Gasbagger Jun. 4 at 12:07 PM

$OPK bills=clown

0 · Reply

tymtested Jun. 4 at 1:00 AM

$OPK statistical probability indicates opko rally could go on 40+ weeks because the base formed across multi year. GO OPKO!

0 · Reply

tymtested Jun. 4 at 12:45 AM

$OPK the only sellers are penny flippers while the stock is headed up. Otherwise, supply of selling is exhausted and more big buyers are accumulating, more aggressively than the sellers.

0 · Reply

tymtested Jun. 3 at 9:51 PM

$OPK new room to run! Bolinger band raised and the resistance raised. GO OPKO!

0 · Reply

tymtested Jun. 3 at 6:19 PM

$OPK get ready for another leg up!! starting to break through resistance!! BIG BUYERS have stepped into the ring!!

0 · Reply

tymtested Jun. 3 at 5:15 PM

$OPK currently trading well above support..

0 · Reply

tymtested Jun. 3 at 5:14 PM

$OPK somebody bought 429,000 shares in the middle of the day today. interesting... probably wasnt dudee..

0 · Reply

Sierradude Jun. 3 at 12:47 PM

$OPK so much for holding above support

1 · Reply

Gasbagger Jun. 3 at 12:37 AM

$OPK Buyers beware ! Management will never share one red cent with with you. 19 to 1 proves that. Sad but true.

0 · Reply

Gasbagger Jun. 2 at 9:27 PM

$OPK why would Corporate want to increase the stock price when its easier just to take the cash ?

0 · Reply

Gasbagger Jun. 2 at 5:52 PM

$OPK the stock price action has NOTHING to do with Shorts. Its all about Corporate Management and the games they play.

0 · Reply

tymtested Jun. 2 at 5:40 PM

$OPK

0 · Reply

tymtested Jun. 2 at 4:17 PM

$OPK Big buyers, institutions, are accumulating opko shares and doing so very carefully not to run the stock up. Clearly they have high expectations for where opko stock is headed! GO OPKO!!

0 · Reply

tradertrash Jun. 2 at 3:22 PM

$OPK Paging dr's take takers and takemore

0 · Reply

Mike18181 Jun. 2 at 11:47 AM

$OPK Promotion was for recovery of Loss in open stock sales to reimburse interested parties. They got back money, so there would not be a Class Action suit for abandonment of fiduciary and Misleading Innocent shareholders. Opko needs a New CEO before they go broke ! Facts !

0 · Reply

Mike18181 Jun. 1 at 10:28 PM

$OPK Stock cant stabilize, its losing money. 1.15 to 1.18 and wajt for the next loss release. Another 66 millio. Loss

0 · Reply

Gasbagger Jun. 1 at 8:25 PM

$OPK the toxic funding for those long term notes is a momentum killer. They just keep selling into the ask. We still dont know who it was that financed that awful deal. Frost hasnt bought a share since the Note Holder recieved all of those shares. Why would he? It sure smells funny. In fact it stinks.

1 · Reply

Market Cap	1.10B
Revenue (ttm)	606.88M
Net Income (ttm)	-225.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-37.19%
Debt to Equity Ratio	0.21

Volume	2,625,400
Avg Vol	2,527,498
Day's Range	N/A - N/A
Shares Out	755.09M
Stochastic %K	85%
Beta	1.50
Analysts	Sell
Price Target	$2.58